Results 241 to 250 of about 6,997,331 (310)
Some of the next articles are maybe not open access.
Blood, 2023
Key Points • Acalabrutinib has a favorable benefit-risk profile, including lower incidence of cardiovascular-related toxicities, vs ibrutinib.• AE burden score allowed further comparison of the safety of acalabrutinib vs ibrutinib accounting for AE ...
J. Seymour +17 more
semanticscholar +1 more source
Key Points • Acalabrutinib has a favorable benefit-risk profile, including lower incidence of cardiovascular-related toxicities, vs ibrutinib.• AE burden score allowed further comparison of the safety of acalabrutinib vs ibrutinib accounting for AE ...
J. Seymour +17 more
semanticscholar +1 more source
Annals of the American Thoracic Society, 2023
RATIONALE Conventional electromagnetic navigation (ENB) and other guided bronchoscopic modalities have a very desirable safety profile but their diagnostic yield is only 60-70% for pulmonary lesions.
M. Ali +4 more
semanticscholar +1 more source
RATIONALE Conventional electromagnetic navigation (ENB) and other guided bronchoscopic modalities have a very desirable safety profile but their diagnostic yield is only 60-70% for pulmonary lesions.
M. Ali +4 more
semanticscholar +1 more source
Cephalalgia, 2021
Objective To assess the safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation. Methods Safety reports of suspected adverse drug reactions were retrieved from VigiBase as of 31 December 2019, for a case-by-case assessment ...
Roberta Noseda +4 more
semanticscholar +1 more source
Objective To assess the safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation. Methods Safety reports of suspected adverse drug reactions were retrieved from VigiBase as of 31 December 2019, for a case-by-case assessment ...
Roberta Noseda +4 more
semanticscholar +1 more source
Safety profile of dirithromycin
Journal of Antimicrobial Chemotherapy, 1993Dirithromycin is a recently developed oral antibiotic, and has been shown to be effective in the treatment of respiratory tract, skin and soft tissue infections. Dirithromycin is administered once daily which may contribute to patient compliance. In this paper we review the data from studies conducted in Europe, USA, Israel and South Africa over a six ...
G D, Sides, P M, Conforti
openaire +2 more sources
Safety profile of the triptans
Expert Opinion on Drug Safety, 2003The triptans are 5-HT(1B/1D) agonists used as migraine and cluster-specific agents. Seven are in commercial use worldwide; in order of release these are sumatriptan, zolmitriptan, rizatriptan, naratriptan, almotriptan, frovatriptan and eletriptan. Sumatriptan has been in clinical use since 1991, and although postmarketing studies have stimulated much ...
Stewart J, Tepper, David, Millson
openaire +2 more sources
Safety profile of levetiracetam
Epileptic Disorders, 2003ABSTRACT A good balance between safety and tolerability is necessary for an antiepileptic drug (AED) to be successful in the management of patients with epilepsy. Levetiracetam is one of the new generation of AEDs licensed as an add‐on therapy for the treatment of patients with partial‐onset seizures.
Santiago, Arroyo, Pamela, Crawford
openaire +2 more sources
European Urology, 1990
Tolerability data from reports to Federal Drug Authorities, information from drug companies, medical literature, and personal experience are cited. Tolerability data regarding norfloxacin were derived from more than 31,000 patients in a phase IV study; ofloxacin from more than 14,000 patients in a phase IV study; and ciprofloxacin from more than 8,000 ...
P M, Shah, R, Mulert
openaire +2 more sources
Tolerability data from reports to Federal Drug Authorities, information from drug companies, medical literature, and personal experience are cited. Tolerability data regarding norfloxacin were derived from more than 31,000 patients in a phase IV study; ofloxacin from more than 14,000 patients in a phase IV study; and ciprofloxacin from more than 8,000 ...
P M, Shah, R, Mulert
openaire +2 more sources
Anti-Cancer Drugs, 1995
This paper reviews the toxicity profile of gemcitabine in a large group of patients (up to 790) from pivotal phase II studies, in which the drug was given intravenously as a 30 min infusion, in a schedule once a week for 3 weeks followed by a week of rest.
M, Tonato, A M, Mosconi, C, Martin
openaire +2 more sources
This paper reviews the toxicity profile of gemcitabine in a large group of patients (up to 790) from pivotal phase II studies, in which the drug was given intravenously as a 30 min infusion, in a schedule once a week for 3 weeks followed by a week of rest.
M, Tonato, A M, Mosconi, C, Martin
openaire +2 more sources